MedTrace Logo

Romiplostim in Chemotherapy-Induced Thrombocytopenia

NCT06201663 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-01-11

No results posted yet for this study

Summary

Prospective interventional randomized controlled trial to assess safety and efficacy of romiplostim in chemotherapy-induced thrombocytopenia in children and adolescents with solid malignancy

Conditions

  • Chemotherapy-induced Thrombocytopenia
  • Solid Malignancy

Interventions

DRUG

Romiplostim

Weekly subcutaneous injections

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-17
Primary Completion
2025-05-31
Completion
2025-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06201663 on ClinicalTrials.gov